Abstracts and Poster Presentations
ClearNote Health is driving innovation in non-invasive cancer detection, with patient needs at the core of everything we pursue. Based on more than 50,000 assays with samples collected across over 150 sites, we have produced multiple abstracts and delivered countless poster presentations covering detection data from several cancer types, including pancreatic and ovarian.
Cell-Free DNA Epigenomic-Based Test Is Predicted to Be Cost-Effective to Manage New-Onset Type 2 Diabetes Patients for Risk of Pancreatic Cancer
November 2024, ISPOR Europe 2024, Barcelona, Spain
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Detection of High-Risk Pancreatic Cysts Using Avantect™ Blood-Based Test
Digestive Disease Week, May, 2024
SAFE-D Trial design: Targeted pancreatic cancer screening to evaluate stage and resectability rate shift in patients with new-onset diabetes.
American Pancreatic Association, December 2023
Implementation of the Avantect Pancreatic Cancer Test in Newly Diagnosed Type 2 Diabetes Patients in a Clinical Setting.
American Diabetes Association 83rd Scientific Sessions, June 2023
Automation of an Early Detection Pancreatic Cancer Test Using 5-Hydroxymethylation Profiles.
Society for Laboratory Automation and Screening, May 2023
Evaluation of the Avantect Pancreatic Cancer Test for Identifying High-Risk Pancreatic Cysts.
American Association for Cancer Research, September 2023
Early detection of pancreatic cancer using 5-hydroxymethylation profiles in plasma-derived cell-free DNA.
American Society of Clinical Oncology, Gastrointestinal Cancers, January 2023